Mae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.
Mae Zakhour, MD
Advertisement
Articles by Mae Zakhour, MD
Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical CancerPublished: March 19th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5